PAVmed Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the fiscal quarter ended* December 31, 2025*, none of our directors or officers (as defined in Rule16a-1 under the Exchange Act) adopted or terminated a “Rule10b5-1 trading arrangement” or “non-Rule10b5-1 trading arrangement” (as those terms are defined in Item408 of Regulation S-K).
In* March 2026,the Company issued225,000* shares of its common stock to an investor relations consultant in consideration of services provided. The offer and sale of the shares of common stock was exempt from the registration requirements of the Securities Act of1933, as amended (the “Securities Act”), pursuant to Section4(a)(2) of the Securities Act, because, among other things, the transaction didnot involve a public offering, the investors are accredited investors, the investors are taking the securities for investment andnot resale and the Company took appropriate measures to restrict the transfer of the securities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.